{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T09:34:46Z","timestamp":1648632886996},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T00:00:00Z","timestamp":1499731200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00520-017-3809-2","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T11:42:53Z","timestamp":1499773373000},"page":"323-324","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["How to report adherence to treatment as clinically relevant data\u2014making a case of CML and TKI"],"prefix":"10.1007","volume":"26","author":[{"given":"Lucas Miyake","family":"Okumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,11]]},"reference":[{"key":"3809_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.2007.02893.x","volume":"63","author":"JK Aronson","year":"2007","unstructured":"Aronson JK (2007) Compliance, concordance, adherence. Br J Clin Pharmacol 63:383\u2013384","journal-title":"Br J Clin Pharmacol"},{"key":"3809_CR2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.leukres.2012.02.032","volume":"36","author":"M Breccia","year":"2012","unstructured":"Breccia M, Efficace F, Alimena G (2012) Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leuk Res 36:804\u2013805","journal-title":"Leuk Res"},{"key":"3809_CR3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00520-016-3486-6","volume":"25","author":"SM Moulin","year":"2017","unstructured":"Moulin SM, Eutr\u00f3pio FJ, Souza JO et al (2017) The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer 25:951\u2013955","journal-title":"Support Care Cancer"},{"key":"3809_CR4","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/sim.2130","volume":"24","author":"B Vrijens","year":"2005","unstructured":"Vrijens B, Goetghebeur E, de Klerk E et al (2005) Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 24:2719\u20132731","journal-title":"Stat Med"},{"key":"3809_CR5","doi-asserted-by":"crossref","first-page":"559","DOI":"10.18549\/PharmPract.2015.02.559","volume":"13","author":"LM Okumura","year":"2015","unstructured":"Okumura LM, Antunes VD, Aguiar KS et al (2015) Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment. Pharm Pract (Granada) 13:559","journal-title":"Pharm Pract (Granada)"},{"key":"3809_CR6","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/cncr.29053","volume":"121","author":"J Guilhot","year":"2015","unstructured":"Guilhot J, Preudhomme C, Mahon FX et al (2015) Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. Cancer 121:490\u2013497","journal-title":"Cancer"},{"key":"3809_CR7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M et al (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348\u2013354","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"3809_CR8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.leukres.2012.01.021","volume":"36","author":"A Gater","year":"2012","unstructured":"Gater A, Heron L, Abetz-Webb L et al (2012) Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 36:817\u2013825","journal-title":"Leuk Res"},{"key":"3809_CR9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691\u2013705","journal-title":"Br J Clin Pharmacol"},{"key":"3809_CR10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ajh.22019","volume":"86","author":"P Ganesan","year":"2011","unstructured":"Ganesan P, Sagar TG, Dubashi B (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471\u2013474","journal-title":"Am J Hematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3809-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3809-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3809-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,3]],"date-time":"2018-01-03T10:42:55Z","timestamp":1514976175000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3809-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,11]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3809"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3809-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,11]]}}}